Candel Therapeutics
CADL
114 hedge funds and large institutions have $213M invested in Candel Therapeutics in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 8 closing their positions.
388% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 8
147% more call options, than puts
Call options by funds: $2.14M | Put options by funds: $869K
82% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 22
59% more capital invested
Capital invested by funds: $134M → $213M (+$79.4M)
36% more funds holding
Funds holding: 84 → 114 (+30)
16.24% more ownership
Funds ownership: 43.05% → 59.29% (+16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$34.9M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$15.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$15M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$6.52M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$6.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$836K |
| 2 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$462K |
| 3 |
Morgan Stanley
New York
|
-$413K |
| 4 |
Barclays
London,
United Kingdom
|
-$314K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$312K |
CADL Hedge Fund Activity: Q1 2026 in Review
114 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q1 2026, worth a combined $213M — up 59% from $134M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CADL positions and 8 closed out — a net gain of 31 holders — while 40 added to existing stakes and 22 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $34.9M. The largest seller was Citadel Advisors, cutting an estimated $836K.
- 114 institutional investors held Candel Therapeutics (CADL) as of Q1 2026, up from 84 in Q4 2025.
- Funds reported $213M of Candel Therapeutics stock for Q1 2026, up 59% quarter-over-quarter.
- 39 funds opened new Candel Therapeutics positions in Q1 2026 and 8 closed out, a net change of +31 holders.
- The largest Candel Therapeutics buyer in Q1 2026 was RTW Investments, an estimated $34.9M added.
- The largest Candel Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $836K sold.
Based on aggregated 13F filings for Q1 2026.